Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 3
2(50.0%)
N/A
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 3(2)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06466382Not ApplicableRecruiting

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Role: lead

NCT05581121Phase 3Recruiting

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Role: collaborator

NCT07397715Recruiting

Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms

Role: lead

NCT04111978Phase 3Recruiting

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

Role: lead

NCT05201001Phase 2Withdrawn

APX005M in Patients With Recurrent Ovarian Cancer

Role: collaborator

All 5 trials loaded